102988-98-7

Basic information

• Product Name: C₁₆H₂₁NO₇
• Synonyms: C₁₆H₂₁NO₇
• CAS NO: 102988-98-7
• Molecular Weight: 339.345
• Mol File: 102988-98-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₁₆H₂₁NO₇(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₂₁NO₇(102988-98-7)
• EPA Substance Registry System: C₁₆H₂₁NO₇(102988-98-7)

Safety Data

• Hazardous Substances Data: 102988-98-7(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 6081-61-4 N-(benzyloxycarbonyl)-D-serine 
• 543-27-1 isobutyl chloroformate 

Downstream Products

• 1197982-99-2 (R)-N-4-(trifluoromethoxy)benzyl 2-(benzyloxycarbonyl)amino-3-methoxypropionamide 
• 1197983-07-5 (R)-N-4-(methoxymethyl)benzyl 2-(benzyloxycarbonyl)amino-3-methoxypropionamide 
• 1197983-06-4 (R)-N-4-(methoxymethyl)benzyl 2-(benzyloxycarbonyl)amino-3-hydroxypropionamide 
• 1197982-98-1 (R)-N-4-(trifluoromethoxy)benzyl 2-(benzyloxycarbonyl)amino-3-hydroxypropionamide 
• 219835-31-1 (R)-N-benzyl 2-N-(benzyloxycarbonyl)amino-3-hydroxypropionamide 

Relevant articles and documents

Synthesis and anticonvulsant activities of (R)-(O)-methylserine derivatives

Efficient procedures for the synthesis of (R)-N-benzyl-2-amino-3- methoxypropionamide ((R)-3), 2-acetamido-3-methoxypropionic acid (4), and O- methylserine (5) are described beginning from (R)-Cbz-serine ((R)-7). The reactions proceeded with little or no racemization and permitted the synthesis of the potent anticonvulsant (R)N-benzyl-2-acetamido-3- methoxypropionamide ((R)-2). The anticonvulsant activities of 2-4 were determined revealing the surprising activity of (R)-2.

NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS

A first aspect of the invention is a compound (sometimes also referred to herein as an "active agent" or "active compound") of Formula (I) or ( Ia): or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.